CBO-001 / CIS Biopharma - LARVOL DELTA

CBO-001, a potential first and best-in-class ADC targeting L1CAM/CD171 with potent anti-tumor efficacy in SCLC and neuroendocrine tumors. (AACR-NCI-EORTC 2025) - "CBO-001 exhibits excellent biophysical properties: 1) low picomolar binding to a clinically validated L1CAM-epitope 2) High specificity with no observed off-target binding in >6'500 human receptors, 3) a homogenous DAR of 8.0, 4) physicochemical and plasma stability superior or comparable to trastuzumab deruxtecan and 5) silenced Fc immune function with retained FcRn receptor binding...CBO-001 caused dose-dependent tumor regression and increased overall survival compared to standard-of-care treatment, cisplatin, by 110% and by 160% compared to the non-treated group. CBO-001-treated animals showed no target or payload-mediated hepatotoxicity, behavioral abnormalities, or adverse events at a concentration up to 10mg/kg. In conclusion, CBO-001 exhibits strong anti-tumor efficacy across L1CAM-positive indications with an excellent safety profile."

Clinical • Colon Cancer • Colorectal Cancer • Gastric Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • L1CAM